Given the clear clinical importance of MCL1 in CLL, we rationalized that targeted inhibition of cdk9 might prove to be a useful therapeutic strategy in CLL and other cancers in which MCL1 is over expressed[30]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.